Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310


Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity.

Stossi F, Dandekar RD, Mancini MG, Gu G, Fuqua SAW, Nardone A, De Angelis C, Fu X, Schiff R, Bedford MT, Xu W, Johansson HE, Stephan CC, Mancini MA.

Nucleic Acids Res. 2020 Jan 13. pii: gkz1172. doi: 10.1093/nar/gkz1172. [Epub ahead of print]


"There is a Place": impacts of managed alcohol programs for people experiencing severe alcohol dependence and homelessness.

Pauly B, Brown M, Evans J, Gray E, Schiff R, Ivsins A, Krysowaty B, Vallance K, Stockwell T.

Harm Reduct J. 2019 Dec 16;16(1):70. doi: 10.1186/s12954-019-0332-4.


Towards personalized treatment for early stage HER2-positive breast cancer.

Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R.

Nat Rev Clin Oncol. 2019 Dec 13. doi: 10.1038/s41571-019-0299-9. [Epub ahead of print] Review.


FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.

Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, Reis-Filho JS, Cohen O, Wagle N, Nardone A, Jeselsohn R, Brown M, Rimawi MF, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2019 Dec 11. pii: 201911584. doi: 10.1073/pnas.1911584116. [Epub ahead of print]


TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.

Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK; , on Behalf of the Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2019 Oct 29. doi: 10.1158/1078-0432.CCR-19-0851. [Epub ahead of print]


Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.

De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2019 Oct 25. doi: 10.1158/1078-0432.CCR-19-1402. [Epub ahead of print]


A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer.

Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, Creighton CJ, Chen F, Dobrolecki LE, George JT, Kumar T, Abdulkareem NM, Mao S, Nardone A, Rimawi M, Osborne CK, Lewis MT, Levine H, Zhang B, Schiff R, Giuliano M, Trivedi MV.

J Clin Med. 2019 Oct 24;8(11). pii: E1772. doi: 10.3390/jcm8111772.


In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer.

Biswal NC, Fu X, Jagtap JM, Shea MJ, Kumar V, Lords T, Roy R, Schiff R, Joshi A.

J Biophotonics. 2020 Jan;13(1):e201900180. doi: 10.1002/jbio.201900180. Epub 2019 Oct 9.


The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.

Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X, Sun Y.

Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20528-20538. doi: 10.1073/pnas.1905973116. Epub 2019 Sep 23.


Medication-related harm in older adults following hospital discharge: development and validation of a prediction tool.

Parekh N, Ali K, Davies JG, Stevenson JM, Banya W, Nyangoma S, Schiff R, van der Cammen T, Harchowal J, Rajkumar C.

BMJ Qual Saf. 2020 Feb;29(2):142-153. doi: 10.1136/bmjqs-2019-009587. Epub 2019 Sep 16.


Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.

Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R.

Mol Cancer Res. 2019 Nov;17(11):2318-2330. doi: 10.1158/1541-7786.MCR-19-0756. Epub 2019 Aug 16.


The Second Conversation project: -Improving training in end of life care communication among junior doctors.

Mathew R, Weil A, Sleeman KE, Bristowe K, Shukla P, Schiff R, Flanders L, Leonard P, Minton O, Wakefield D, St John K, Carey I.

Future Healthc J. 2019 Jun;6(2):129-136. doi: 10.7861/futurehosp.6-2-129.


HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2020 Jan 1;112(1):46-54. doi: 10.1093/jnci/djz042.


Deficits in statistical leaning of auditory sequences among adults with dyslexia.

Kahta S, Schiff R.

Dyslexia. 2019 May;25(2):142-157. doi: 10.1002/dys.1618. Epub 2019 Apr 21.


On the outside looking in: Finding a place for managed alcohol programs in the harm reduction movement.

Ivsins A, Pauly B, Brown M, Evans J, Gray E, Schiff R, Krysowaty B, Vallance K, Stockwell T.

Int J Drug Policy. 2019 May;67:58-62. doi: 10.1016/j.drugpo.2019.02.004. Epub 2019 Apr 6.


Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance.

Zhou Y, Gerrard DL, Wang J, Li T, Yang Y, Fritz AJ, Rajendran M, Fu X, Schiff R, Lin S, Frietze S, Jin VX.

Nat Commun. 2019 Apr 3;10(1):1522. doi: 10.1038/s41467-019-09320-9.


A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Veeraraghavan J, Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.

Ann Oncol. 2019 Jun 1;30(6):927-933. doi: 10.1093/annonc/mdz076.


Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.

Ramirez AB, Bhat R, Sahay D, De Angelis C, Thangavel H, Hedayatpour S, Dobrolecki LE, Nardone A, Giuliano M, Nagi C, Rimawi M, Osborne CK, Lewis MT, Stilwell JL, Kaldjian EP, Schiff R, Trivedi MV.

BMC Cancer. 2019 Mar 12;19(1):220. doi: 10.1186/s12885-019-5382-1.


Understanding the Fertility Desires and Intentions among HIV-Positive Men Living in Ontario: Survey Instrument Development and Validation.

Djiometio JN, Antoniou T, Kristman V, Schiff R, Gamble M, Kennedy L, Yudin M, Loutfy M.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219831018. doi: 10.1177/2325958219831018.


The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.

Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R.

Br J Cancer. 2019 Feb;120(3):331-339. doi: 10.1038/s41416-018-0354-9. Epub 2018 Dec 17.


Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer.

Guarducci C, Bonechi M, Benelli M, Biagioni C, Boccalini G, Romagnoli D, Verardo R, Schiff R, Osborne CK, De Angelis C, Di Leo A, Malorni L, Migliaccio I.

NPJ Breast Cancer. 2018 Nov 28;4:38. doi: 10.1038/s41523-018-0092-4. eCollection 2018.


Comparison of the Diagnostic Accuracy of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients <80 to those >80 Years of Age with Heart Failure.

Draper J, Webb J, Jackson T, Jones H, Rinaldi CA, Schiff R, McDonagh T, Razavi R, S Carr-White G.

Am J Cardiol. 2018 Dec 15;122(12):2075-2079. doi: 10.1016/j.amjcard.2018.09.004. Epub 2018 Sep 13.


AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.

Campbell PS, Mavingire N, Khan S, Rowland LK, Wooten JV, Opoku-Agyeman A, Guevara A, Soto U, Cavalli F, Loaiza-Pérez AI, Nagaraj G, Denham LJ, Adeoye O, Jenkins BD, Davis MB, Schiff R, Brantley EJ.

J Cell Physiol. 2018 Jan;234(1):108-121. doi: 10.1002/jcp.27013. Epub 2018 Aug 4.


The origin of the centrality deficit in individuals with attention-deficit/hyperactivity disorder.

Yeari M, Vakil E, Schifer L, Schiff R.

J Clin Exp Neuropsychol. 2019 Feb;41(1):69-86. doi: 10.1080/13803395.2018.1501000. Epub 2018 Aug 1.


Evidence and tips on the use of medication compliance aids.

Furmedge DS, Stevenson JM, Schiff R, Davies JG.

BMJ. 2018 Jul 19;362:k2801. doi: 10.1136/bmj.k2801. No abstract available.


Can doctors identify older patients at risk of medication harm following hospital discharge? A multicentre prospective study in the UK.

Parekh N, Stevenson JM, Schiff R, Graham Davies J, Bremner S, Van der Cammen T, Harchowal J, Rajkumar C, Ali K; PRIME study group.

Br J Clin Pharmacol. 2018 Oct;84(10):2344-2351. doi: 10.1111/bcp.13690. Epub 2018 Jul 30.


Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK.

Parekh N, Ali K, Stevenson JM, Davies JG, Schiff R, Van der Cammen T, Harchowal J, Raftery J, Rajkumar C; PRIME study group.

Br J Clin Pharmacol. 2018 Aug;84(8):1789-1797. doi: 10.1111/bcp.13613. Epub 2018 May 31.


Development and Relationships Between Phonological Awareness, Morphological Awareness and Word Reading in Spoken and Standard Arabic.

Schiff R, Saiegh-Haddad E.

Front Psychol. 2018 Apr 9;9:356. doi: 10.3389/fpsyg.2018.00356. eCollection 2018.


Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES.

Mol Cancer Ther. 2018 May;17(5):921-930. doi: 10.1158/1535-7163.MCT-17-0302. Epub 2018 Mar 28.


Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.


GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.

Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, Al-Rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar VA, Osborne CK, Schiff R, Trivedi MV.

Breast Cancer Res Treat. 2018 Jul;170(2):279-292. doi: 10.1007/s10549-018-4751-9. Epub 2018 Mar 24.


Community managed alcohol programs in Canada: Overview of key dimensions and implementation.

Pauly BB, Vallance K, Wettlaufer A, Chow C, Brown R, Evans J, Gray E, Krysowaty B, Ivsins A, Schiff R, Stockwell T.

Drug Alcohol Rev. 2018 Apr;37 Suppl 1:S132-S139. doi: 10.1111/dar.12681. Epub 2018 Mar 24.


Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize.

Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV.

Cancer Res. 2018 Feb 15;78(4):845-852. doi: 10.1158/0008-5472.CAN-17-2748. Epub 2018 Feb 2.


Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.

Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K.

Cancer Res. 2018 Feb 1;78(3):671-684. doi: 10.1158/0008-5472.CAN-17-1327. Epub 2017 Dec 6.


PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.

Ito K, Park SH, Katsyv I, Zhang W, De Angelis C, Schiff R, Irie HY.

NPJ Breast Cancer. 2017 Nov 17;3:45. doi: 10.1038/s41523-017-0047-1. eCollection 2017.


Introduction to Special Issue: Spelling and Morphology in Different Orthographies among Readers with and without Dyslexia.

Schiff R, Joshi RM.

Dyslexia. 2017 Nov;23(4):319-323. doi: 10.1002/dys.1573. No abstract available.


The role of feedback in implicit and explicit artificial grammar learning: a comparison between dyslexic and non-dyslexic adults.

Schiff R, Sasson A, Star G, Kahta S.

Ann Dyslexia. 2017 Oct;67(3):333-355. doi: 10.1007/s11881-017-0147-5. Epub 2017 Nov 13.


Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.


A multi-centre randomised trial to compare the effectiveness of geriatrician-led admission avoidance hospital at home versus inpatient admission.

Shepperd S, Cradduck-Bamford A, Butler C, Ellis G, Godfrey M, Gray A, Hemsley A, Khanna P, Langhorne P, McCaffrey P, Mirza L, Pushpangadan M, Ramsay S, Schiff R, Stott D, Young J, Yu LM.

Trials. 2017 Oct 23;18(1):491. doi: 10.1186/s13063-017-2214-y.


Development of quality metrics for ambulatory care in pediatric patients with tetralogy of Fallot.

Villafane J, Edwards TC, Diab KA, Satou GM, Saarel E, Lai WW, Serwer GA, Karpawich PP, Cross R, Schiff R, Chowdhury D, Hougen TJ.

Congenit Heart Dis. 2017 Dec;12(6):762-767. doi: 10.1111/chd.12523. Epub 2017 Sep 7. Review.


Infective endocarditis in adults with congenital heart disease remains a lethal disease.

Tutarel O, Alonso-Gonzalez R, Montanaro C, Schiff R, Uribarri A, Kempny A, Grübler MR, Uebing A, Swan L, Diller GP, Dimopoulos K, Gatzoulis MA.

Heart. 2018 Jan;104(2):161-165. doi: 10.1136/heartjnl-2017-311650. Epub 2017 Jul 28.


De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.

Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, Osborne CK, Schiff R.

Breast. 2017 Aug;34 Suppl 1:S19-S26. doi: 10.1016/j.breast.2017.06.022. Epub 2017 Jul 4. Review.


Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.

Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4482-E4491. doi: 10.1073/pnas.1620993114. Epub 2017 May 15.


HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.


Effect of chunk strength on the performance of children with developmental dyslexia on artificial grammar learning task may be related to complexity.

Schiff R, Katan P, Sasson A, Kahta S.

Ann Dyslexia. 2017 Jul;67(2):180-199. doi: 10.1007/s11881-017-0141-y. Epub 2017 Apr 13.


The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Jeselsohn R, De Angelis C, Brown M, Schiff R.

Curr Oncol Rep. 2017 May;19(5):35. doi: 10.1007/s11912-017-0591-8. Review.


Spelling and Morphology in Dyslexia: A Developmental Study Across the School Years.

Schiff R, Levie R.

Dyslexia. 2017 Nov;23(4):324-344. doi: 10.1002/dys.1549. Epub 2017 Jan 25.


Online and offline inferential and textual processing of poor comprehenders: Evidence from a probing method.

Yeari M, Elentok S, Schiff R.

J Exp Child Psychol. 2017 Mar;155:12-31. doi: 10.1016/j.jecp.2016.10.011. Epub 2016 Nov 25.


Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.

Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, Schiff R, Wang XS, Li K.

Oncogene. 2017 May 18;36(20):2910-2918. doi: 10.1038/onc.2016.433. Epub 2016 Nov 28.

Supplemental Content

Loading ...
Support Center